Celgene Co. (CELG) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. reduced its stake in shares of Celgene Co. (NASDAQ:CELG) by 0.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,427,873 shares of the biopharmaceutical company’s stock after selling 20,830 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Celgene were worth $354,032,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Thompson Davis & CO. Inc. raised its holdings in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares during the period. Arcadia Investment Management Corp MI raised its holdings in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares during the period. Guidant Wealth Advisors acquired a new stake in Celgene during the 3rd quarter worth approximately $119,000. Motco raised its holdings in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares during the period. Finally, Penserra Capital Management LLC acquired a new stake in Celgene during the 2nd quarter worth approximately $129,000. Hedge funds and other institutional investors own 79.74% of the company’s stock.

CELG has been the topic of several research analyst reports. BMO Capital Markets raised their target price on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, November 17th. Oppenheimer reiterated a “buy” rating and issued a $170.00 price objective on shares of Celgene in a report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a report on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $131.18.

Celgene Co. (NASDAQ CELG) opened at $106.00 on Friday. The firm has a market cap of $83,455.60, a price-to-earnings ratio of 25.18, a P/E/G ratio of 0.68 and a beta of 1.77. Celgene Co. has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.58 earnings per share. analysts anticipate that Celgene Co. will post 6.69 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/14/celgene-co-celg-shares-sold-by-sumitomo-mitsui-trust-holdings-inc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit